跳至主要内容
临床试验/EUCTR2015-002189-21-IT
EUCTR2015-002189-21-IT进行中(未招募)1 期

The combined effect of subcutaneous Granulocyte - Colony Stimulating Factor and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride on post-infarction left ventricular function¿ - ND

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 120 人开始时间: 2021年5月27日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Signed and dated informed consent
  • 2. Men and women of any ethnic origin aged = 18 years
  • 3. Patients with acute ST-elevation myocardial infarction as defined by the universal definition of AMI.
  • 4. Successful acute reperfusion therapy (residual stenosis visually <50% and TIMI flow =2) within 24 hours of symptom onset by successful percutaneous coronary intervention (PCI) or thrombolysis within 12 hours of symptom onset followed by successful PCI within 24 hours after thrombolysis
  • 5. Left ventricular ejection fraction = 45% at 24 hours after revascularization, as documented by a two-dimensional echocardiogram.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 60

排除标准

  • 1.Participation in another clinical trial within 30 days prior to randomisation
  • 2.Pregnant or nursing women or women in childbearing age not able to esclude the possibility of a pregnancy
  • 3.Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol
  • 4.Necessity to revascularise additional vessels, outside the target coronary artery after investigational therapy/placebo administration (additional revascularisations after primary PCI and before investigational therapy/placebo administration are allowed)
  • 5.Persistent cardiogenic shock
  • 6.Known hematologic and neoplastic diseases
  • 7.Severe impaired renal function, i.e. GFR<30 ml/min
  • 8.Persistent fever or diarrhoea not responsive to treatment within 4 weeks prior screening or severe infection
  • 9.Uncontrolled hypertension (systolic >180 mmHg and diastolic >120 mmHg)
  • 10.Life expectancy of less than 2 years from any non-cardiac cause or neoplastic disease

研究者

发起方
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

相似试验

尚未招募
3 期
Effect of Granulocyte colony stimulating factor (G-CSF) on in-vitro fertilization (IVF) results
IRCT20230718058835N1Hamedan University of Medical Sciences134
已完成
4 期
Impact of the Granulocytes Colony-Stimulating Factor (ior-LeukoCIM) in primary and secondary prophylaxis and post chemotherapy and/or radiotherapy neutropenia in oncohematological pediatric patients.eutropenia secondary to chemo and/or radiotherapy.
RPCEC00000084Center of Molecular Immunology(CIM)372
已完成
不适用
The study of the combination effect of granulocyte/monocyte adsorptive apheresis in Crohn&#39;s disease patients who lose response to Infliximab therapyCrohn's disease
JPRN-UMIN000035185Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University10
招募中
不适用
Therapeutic effect of granulocyte and monocyte adsorption column (Adacolumn) for refractory skin diseasesInflammatory keratosis (psoriasis vulgaris, psoriasis arthropica), neutrophilic dermatosis (pustular psoriasis, palmoplantar pustulosis, Behcet disease, Sweet disease, gangrene pyoderma, erythema elevatum diutinum) , vasculitis syndrome (nodular arteritis, cutaneous allergic vasculitis, Schonlein-Henoch purpura, Wegener&#39s granulomatosis), eosinophilic disease (hypereosinophilic syndrome, atopic dermatitis), etc
JPRN-UMIN000021070Kagoshima University60
招募中
1 期
Study the effect of Granulocyte colony stimulating factor (G-CSF) influence on neurological and cardiac toxicity caused by carbon monoxide in patients with carbon monoxide poisoning
IRCT201607232083N7Management and technology assistance of Mashhad university of medical sciences, school of pharmac40